|
|
 |
|
Viewing report
|
|
|
|
Commercial Insight: Osteoarthritis - Market Sees Steady Growth
Datamonitor, Dec 2006, Pages: 155
The 2004 withdrawal of Vioxx from the global market had a negative effect on the COX-2 class, with a 44% fall in Celebrex sales for osteoarthritis in 2005. However, as patients sought an alternative to the COX-2s, there was positive growth in traditional NSAIDs, non-narcotic analgesics, narcotic analgesics, corticosteroids and HA viscosupplements, leading to a 1.1% increase in total market value.
Scope of this title:
- Sales and volume forecasts for the leading osteoarthritis therapies to 2015, calculated for the osteoarthritis indication alone
- Assessment of current and future opportunities and threats in the osteoarthritis market across the seven major pharmaceutical markets
- Key events that may affect revenues are applied and discussed for each of the seven major pharmaceutical markets.
- Case studies outline future strategies companies will use for advertising and marketing COX-2 inhibitors and the factors behind the success of Synvisc
Highlights of this title:
- The osteoarthritis market is forecast to grow steadily, and will reach $7 billion by 2015. Growth comes from expanded use of hyaluronic acids and pipeline products launches. Despite competition from COX-2s such as Prexige and Arcoxia, Pfizers Celebrex to remain the leading brand until patent expiry in 2014.
- After the withdrawal of Vioxx over CV safety fears, Merck was criticized for its heavy marketing campaign. Companies should target their products to specific populations rather than the population as a whole, shift to eSampling and continue to conduct large-scale safety studies.
- Synvisc sales will reach $300 million by 2015. Indication expansions in the US and EU, and launch in Japan, will drive sales. Future opportunities in the HA market will come from the development of single injection products. The EU markets show good opportunity for HAs with the highest growth.
Reasons to order your copy:
- Assess the impact of events such as patent expiries and indication expansion on the osteoarthritis sales of key brand name products
- Quantify the future size of the market, in terms of volume and value, for the osteoarthritis indication in each of the seven major markets
- Understand strategies that pharmaceutical companies will use to market COX-2s in the future.
Products Mentioned Include:
- Celebrex (celecoxib)
- Arcoxia (etoricoxib)
- Mobic (meloxicam)
- Voltaren (diclofenac)
- Arthrotec (diclofenac + misoprostol)
- Aleve (naproxen)
- Tramal (tramadol)
- Synvisc (hylan G-F 20)
Customers who bought this item also bought
Forecast Insight: Osteoarthritis
Stakeholder Insight: Osteoarthritis - COX-2s wear down traditional NSAID use
Pipeline Insight: Osteoarthritis - The Wait for a DMOAD Continues
Event Analysis and Response Service: Cox-2s - Cox-2 Crisis Dents Big Pharma Confidence
Commercial Insight: Osteoarthritis and Rheumatoid Arthritis - New Growth In A Mature Market
COX-2 withdrawal - Therapeutic, R&D and pharmaceutical impact
Vioxx Recall - Revenue Analysis and Impact on Cox-2 Inhibitor Markets
Collagen and HA-Based Biomaterials - Global Strategic Business Report
Osteoarthritis - Preconceptions Damage Awareness and Treatments
The Vioxx Withdrawal: Changes and Opportunities for the Industry
COX-2 Inhibitors - Biology, Therapeutic Agents & Markets
U.S. Markets for Biomaterial Applications of Hyaluronic Acid (HA)
|
|
|
|
